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referral processes. It was launched in 2007. Potential participants (PP) 
age 49, with or without cognitive concerns, access the Registry via out-
reach events, telephone, or the Internet (www.registry.azalz.org). An initial
intake form is completed and questions are addressed by telephone. Inter-
ested PP’s receive a welcome packet, consent form, and medical history
form; these are reviewed by telephone upon their return. Cognitive screen-
ing occurs via a cognitive and functional questionnaire and the modified
Telephone Interview based Cognitive Screen (TICSm); those with ambig-
uous scores undergo a version of the Auditory Verbal Learning Task (Rey
AVLT). Based on review of medical information and testing, PP’s are
categorized as probably cognitively normal, possibly cognitively impaired,
or probably demented, and referred to existing AAC studies or held for
future referral. Results: The database stores PP contact information, re-
search interest, cognitive status, demographics and referral information.
After consent, it is used to track and facilitate PP enrollment and contacts,
store comprehensive medical information, facilitate cognitive testing, and
initiate and track study referrals with the AAC. It also catalogues clinical
study and site information for all AAC sites. Conclusions: A companion
presentation (Arizona Alzheimer’s Registry II: Progress and Data from
Year 1; Holt et al) summarizes the unexpected early success of this
initiative, which may offer a model for other organizations.
P4-397 MEMANTINE TREATMENT PREVENTS
CLINICAL WORSENING: A POOLED ANALYSIS
OF PATIENTS WITH MODERATE TO SEVERE
ALZHEIMER’S DISEASE
Michael Tocco, Stephen M. Graham, Forest Research Institute, Jersey
City, NJ, USA. Contact e-mail: Michael.Tocco@frx.com
Background: Memantine, a moderate-affinity, uncompetitive NMDA recep-
tor antagonist, is approved in several countries, including the U.S. and those in
the European Union, for the treatment of moderate to severe Alzheimer’s
disease (AD). This analysis sought to combine the data from three double-
blind, placebo-controlled trials in moderate to severe AD and to compare the
numbers of memantine (10 mg, BID)- and placebo-treated patients who dem-
onstrated a clinical decline from baseline on measures of cognition (SIB),
function (ADCS-ADL19), global status (CIBIC-Plus), and behavior (NPI). In
the context of this progressive neurodegenerative disease, focusing on preven-
tion of worsening may provide more realistic treatment expectations for pa-
tients and clinicians. Methods: The data were pooled from 3 clinical trials in
moderate to severe AD (2 memantine monotherapy studies, MEM-MD-01 and
MRZ-90001-9605, and 1 memantine plus donepezil combination study,
MEM-MD-02). For each outcome measure, we used a generalized estimating
equations model to compare the proportions of memantine- and placebo-
treated patients (observed cases) who experienced a decline from baseline at
Week 12, Week 24/28 (study endpoint), and across the entire trial (overall).
Results: On all outcome measures, significantly fewer memantine-treated
patients experienced clinical decline at Week 12, Week 24/28, and overall,
compared to placebo-treated patients. At Week 24/28, the percentages of
placebo- and memantine-treated patients who demonstrated clinical worsening
were, respectively: 55.8% vs 44.7% on the SIB (P0.001), 65.6% vs 56.2%
on the ADCS-ADL (P0.006), 53.2% vs 42.2% on the CIBIC-Plus
(P0.002), and 46.8% vs 39.7% on the NPI (P0.048). Conclusions: The
current study suggests that significantly fewer patients treated with memantine
demonstrate clinical worsening after 6 months of treatment, compared to
patients treated with placebo. These findings lend further support to the
efficacy of memantine treatment in patients with moderate to severe AD.
P4-398 IDENTIFYING COGNITIVE ENHANCEMENT IN
MAN: ADDING TESTING TO ROUTINE PHASE I
TRIALS
Patrick Turk1, Nicole Meinel2, Steve Satek1, James M. Ferguson1,
Brian Saxby2, Keith Wesnes2, 1Cognitive Drug Research Ltd, Chicago,
IL, USA; 2Cognitive Drug Research Ltd, Goring-on-Thames, United
Kingdom. Contact e-mail: patrickt@cognitivedrugresearch.com
Background: One of the challenges for translational medicine over the last
three decades has been to convince skeptics that cognitive function can be
improved in healthy young volunteers. Now that an incontrovertible body of
evidence has accumulated to show that this is possible, the opportunity to add
cognitive testing to routine Phase I studies in order to identify potential
cognition enhancement is becoming routine practice. Methods: This paper
will review the use of the Cognitive Drug Research (CDR) computerized
assessment system in over 25 such studies, and will identify the core aspects
of test design which makes possible this integration of pharmacodynamic
testing into trials whose primary purpose is safety and tolerability. Results:
The trials reviewed will all have involved the simple addition of CDR testing
to routine single and multiple dose trials, without an increase in subject
number, study duration or at the expense of the primary objectives of such
work - the safety of the volunteers and the identification of the tolerability of
the compounds. Drugs with a diverse range of mechanisms of action will be
covered, but special attention will be devoted to several of the selective
nicotinic acetylcholine receptor agonists which are under development, includ-
ing TC1734/AZD3480 and MEM3454. Conclusions: The paper will conclude
that adding cognitive testing to routine Phase I trials is fast becoming a routine
tool in translational medicine which has repeatedly shown its value, not only
by identifying suitable targets for further development, but also by facilitating
co-licensing deals.
P4-399 THE SOMATOTROPHICS, MEMORY AND AGING
RESEARCH TRIAL (SMART): STUDY OF
MENTAL ACTIVITY & RESISTANCE TRAINING
FOR THE PREVENTION OF COGNITIVE
IMPAIRMENT IN AT-RISK OLDER INDIVIDUALS
Michael Valenzuela1, Maria Fiatarone Singh2, Nalin Singh2,
Bernhard Baune3, Wei Wen1, Henry Brodaty1, Perminder Sachdev1,
1University of New South Wales, Sydney, Australia; 2University of
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Background: Epidemiological, basic science and clinical evidence suggests
that cognitive and physical exercise may benefit brain function in late life.
Potentially protective neurobiological effects include adaptations in cortical
volume, neuropeptides, functional activation, cytokines, body composition and
insulin sensitivity. Delaying the onset of dementia and age-related cognitive
impairment through cognitive and physical activity may therefore be a realistic
goal, however this has yet to be fully tested in a RCT. In particular, the
possibility of synergistic effects between cognitive and physical activity has
not been robustly evaluated. Methods: A fully factorial, double-blind, placebo
controlled and longitudinal randomized clinical trial. 182 initially non-de-
mented older individuals at-risk for dementia by virtue of borderline cognitive
function will be recruited and randomly assigned to one of four intervention
conditions in equal numbers. Eligible individuals will be older than 65 years
without dementia or depression, physically and linguistically capable of com-
pleting supervised cognitive and physical exercise, and at-risk defined as
corrected MMSE 23-27. Interventions: 1. Cognitive exercise: 6 months of
thrice weekly 1 hour sessions of computer-based multi-modal cognitive exer-
cise plus sham physical exercise (stretching). 2. Physical exercise: 6 months of
thrice weekly 1 hour sessions of progressive resistance exercise plus sham
cognitive exercise (lectures). 3. Combined exercise: both active cognitive and
physical exercise. 4. Double Sham Control group: both sham cognitive and
physical exercise. Results: Will occur at 0 (baseline), 6 months (immediately
after the intervention: proximal follow-up) and 18 months (longitudinal fol-
low-up). These will include: Neuropsychological battery including ADAS-
Cog; Neuropsychiatric evaluation; Magnetic Resonance Imaging (MRI) brain
scans; Mood and well-being; Physical fitness and functional performance; and
Systemic inflammation, metabolism, nutritional biochemistry. Conclusions:
Primary: To determine whether active interventions lead to a differential rate
of cognitive decline at longitudinal follow-up compared to the placebo group,
and whether combined mental and physical exercise is more effective than
either modality alone. Secondary: To determine whether active intervention
effects are mediated by specific changes in brain structure and function, or via
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alterations in metabolism, body composition or systemic inflammation. To
determine whether active intervention effects are associated with improved
mood and well-being.
P4-400 A RETROSPECTIVE, OBSERVATIONAL STUDY
OF COGNITIVE, BEHAVIORAL AND
FUNCTIONAL OUTCOMES IN MILD TO
MODERATE ALZHEIMER PATIENTS TREATED
WITH CHOLINESTERASE INHIBITORS, OR
WITH GINGKO BILOBA OR MEMANTINE
Guy Van Den Abeele, AZ St. Lucas, Gent, Belgium. Contact e-mail:
gvda@telenet.be
Background: A total of 448 patients were enrolled since December until
August 2007 meeting the criteria for dementia of DSM IV, including a
recent computerized tomographic scan or magnetic resonance imaging
compatible with an AD diagnosis. The distribution of the initial medicatons
encompass 42% donepezil, 25% rivastigmine, 23% galantamine, 5%
gingko biloba (EGb 761) and 5% memantine. The patients were referred to
the neurologic department of a general hospital, and enrolled by Prof. dr.
J. De Bleecker, MD and myself. Methods: Cognitive, functional and
behavioral status measurement using following scales: MMSE,GDS,ADL,
IADL and NPI. These measures were obtained at baseline and at 6 months
and then each year again. Results: Possible differential efficacy of the
various medications are currently being analysed by Prof.Georges Van
Maele, Dpt Medical Informatics & Statistics, University Hospital 5K3, De
Pintelaan 185, 9000 Gent, Belgium. Conclusions: we expect to do some
inferences concerning the course of the disease and the possible impact of
the various medications.
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MAN: IDENTIFYING EFFICACY IN THE
DEMENTIAS
Keith Wesnes1, Steve Satek2, James M. Ferguson2, Patrick Turk2,
Brian Saxby1, 1Cognitive Drug Research Ltd, Goring-on-Thames, United
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Background: The limitations of the ADAS-cog as a tool to assess the efficacy
of drugs to treat Alzheimer’s disease are becoming widely recognized. One
major deficiency is that it does not assess attention, and this limitation is even
more serious in other dementias where deficits to attention are recognized as
primary diagnostic symptoms, e.g. Dementia with Lewy bodies and Parkin-
son’s disease dementia. The case for an automated test battery such as the
Cognitive Drug Research (CDR) computerized assessment system to replace
the ADAS-cog in Phase III trials has been made (Wesnes K, Neurodegenera-
tive Disorders 2008, in press). However, this transition has already started in
Phase II, where the ADAS-cog is unarguably unsuitable as it requires studies
the size of typical Phase III trials to detect benefits. Methods: Data will be
presented from a variety of compounds showing the sensitivity of the CDR
system in various Phase II studies, including novel data from the first Alzhei-
mer’s trial with a selective nicotinic agonist, MEM3454, in which the CDR
System was the primary outcome. Results: The suitability of the CDR system,
even in small Phase IIa trials, makes it particularly suitable for this crucial
stage of translational medicine. Work in which the CDR system was a co-
primary endpoint in the first randomized trial of an anticholinesterase in
Dementia with Lewy bodies will also be reported, as will data from the trial on
which the regulatory decision to allow rivastigmine to be prescribed to treat the
cognitive deficits in Parkinson’s disease dementia was based. Conclusions: It
is concluded that the use of systems like the CDR which properly and
sensitively assess the full range of cognitive deficits in the dementias will help
identify the full therapeutic potential of future treatments. This should help
avoid a repetition of the widely criticized recommendation by the National
Institute for Clinical Excellence that all Alzheimer’s drugs should no longer be
used in the treatment of mild to moderate Alzheimer’s disease in the UK.
P4-402 BASELINE COGNITIVE AND DEMOGRAPHIC
CHARACTERISTICS OF WOMEN ENROLLED IN
THE KRONOS EARLY ESTROGEN PREVENTION
STUDY (KEEPS)
Whitney Wharton1, Carey E. Gleason1, Eliot Brinton2,
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Francisco, San Francisco, CA, USA; 4Columbia University, New York,
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6University of Washington School of Medicine, Tacoma, WA, USA;
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Background: The KEEPS (Kronos Early Estrogen Prevention Study) Cogni-
tive and Affective Study (KEEPS C/A) is a multisite, randomized, placebo-
controlled, double-blind, parallel-group design addressing major hormone-
related issues raised by recent findings of WHIMS. The objective of the
KEEPS C/A Study is to evaluate differential efficacy of oral conjugated equine
estrogen (CEE or Premarin®) and transdermal 17 -estradiol (tE2) with 12
days/month progesterone (Prometrium®) on mood and cognition in healthy
non-hysterectomized, women who are within 6 months - 3 years of meno-
pause. The KEEPS C/A Study will be conducted over 4 years. Methods:
Outcome measures include cognitive and mood tests administered at baseline
and months 18, 36 and 48 during treatment. Of these, month 36 evaluation
investigates potential progestational effects while months 18 and 48 examine
estrogenic effects. Affective measures include: Profile of Mood States Ques-
tionnaire (POMS), Memory Function Questionnaire (MFQ), Beck Depression
Inventory (BDI) and PRIME-MD. The cognitive battery includes: Prospective
Memory Test, Modified Mini-Mental State Examination (MMSE2), NYU
Paragraphs, Stroop, Digit Symbol, WMS-3 Letter-Number Sequencing, Cali-
fornia Verbal Learning Test 2 (CVLT-2), Mental Rotation, Visual Search,
Benton Visual Retention Test and Verbal Fluency. Results: To date, the
KEEPS C/A Study has enrolled 671 women, average age (mean SD)
53.72.5 years. Approximately 77% of subjects are Caucasians, while 23%
are of minority origin. Most participants report an annual income over $40,000
and have at least a high school diploma. At baseline, mean BMI is 26.2 4.6
kg/mm2, laboratory values (mg/dL) are: Total cholesterol 21531.8, HDL
cholesterol 65.017.2, LDL cholesterol 129.929.3, triglycerides 91.251.0,
and fasting glucose 89.09.9. All women are cognitively healthy (MMSE2
28.9  2.1). Interestingly, a positive relationship (r  .150, p  .01) is
observed between plasma estradiol and MMSE2 total score. Conclusions:
Baseline physiological, cognitive and affective data in the KEEPS C/A Study
indicate that the cohort is healthy and free of cognitive dysfunction. The
correlation between estradiol and MMSE score supports prior data reporting
estradiol’s salutary effect on cognition.
P4-403 EXTENDED-RELEASE (ER) MEMANTINE
CAPSULE (28 MG, ONCE DAILY): A MULTIPLE-
DOSE, OPEN-LABEL STUDY EVALUATING
STEADY-STATE PHARMACOKINETICS IN
HEALTHY VOLUNTEERS
Antonia Periclou, Yiqun Hu, Forest Research Institute, Jersey City, NJ,
USA. Contact e-mail: Antonia.Periclou@frx.com
Background: Memantine is a moderate-affinity, uncompetitive antagonist of
N-methyl-D-aspartate (NMDA) receptors, indicated for the treatment of mod-
erate to severe Alzheimer’s disease (AD). Approved memantine administra-
tion is 10 mg twice daily (20 mg/day), in the form of an immediate-release (IR)
tablet or solution. In this study, we investigated the safety, tolerability, and
pharmacokinetics of an extended-release (ER) memantine capsule (28 mg) in
healthy volunteers. Methods: In this Phase I, single-center, open-label study,
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